Subsequent clinical trials have confirmed that targeted inhibition of the PD-1/PD-L1 signaling pathway can continuously activate anti-tumor immune response, inhibit tumor growth, and reduce the disease burden of patients. The gene discussed is CD274; the disease is neoplasm.